Associated Papers
Pharmacogenetic study of CES1 gene and enalapril efficacy.
Hussain M et al.
Journal of Applied Genetics, 2024
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.
Liu Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2024
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M et al.
Clinical Pharmacokinetics, 2023
Functional Study of Carboxylesterase 1 Protein Isoforms.
Wang X et al.
Proteomics, 2019
Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.
Myer NM et al.
Molecular Psychiatry, 2018
Clinical implications of genetic variation in carboxylesterase drug metabolism.
Chen F et al.
Expert Opinion on Drug Metabolism & Toxicology, 2018
CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.
Wang X et al.
The Pharmacogenomics Journal, 2016
CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.
Zhu HJ et al.
European Journal of Clinical Pharmacology, 2016
Prognostic impact of carboxylesterase 1 gene variants in patients with congestive heart failure treated with angiotensin-converting enzyme inhibitors.
Nelveg-Kristensen KE et al.
Pharmacogenetics and Genomics, 2016
Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
Johnson KA et al.
Journal of Child and Adolescent Psychopharmacology, 2013
Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit/hyperactivity disorder treated with methylphenidate.
Bruxel EM et al.
The Pharmacogenomics Journal, 2013
Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.
Zhu HJ et al.
The Journal of Pharmacology and Experimental Therapeutics, 2013
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K et al.
British Journal of Clinical Pharmacology, 2010
Select a paper to view details